- The Medicare GLP-1 Bridge Program will allow eligible Medicare beneficiaries to access Wegovy and Zepbound for a $50 monthly copay, expanding treatment for obesity despite shrinking private insurance coverage.
- Eligibility rules, prior authorization requirements, and exclusions from Part D subsidy benefits may still make access difficult for many lower-income seniors.
- While the program improves affordability, experts say its long-term success will depend on clear guidance, permanent Medicare coverage reforms, and easier enrollment processes.
DEBORAH FINLEY’S 90 DAYS
Deborah Finley, 50, of Lodi, California, remembers exactly when her fear about her weight became concrete. It was during COVID, watching the news, noticing that the people on ventilators, the people who didn’t make it, disproportionately shared something with her: obesity. She had sleep apnea, nonalcoholic fatty liver disease, and was prediabetic. Then, at the end of last year, her insurer sent a notice: they were dropping coverage for Zepbound, the GLP-1 medication that had been managing her weight. ‘We’re giving you 90 days’ notice to figure out what you want to do,’ the letter said.
Finley’s situation is not unusual. It is, increasingly, the norm. According to research by GoodRx, between 2025 and 2026, 12 million people were on insurance plans that dropped coverage for Zepbound, and another 12 million lost coverage for Wegovy, the other leading GLP-1 medication. Against that backdrop of contracting private coverage, the federal government’s new Medicare GLP-1 Bridge program, launching July 1, 2026, represents a rare moment of expanding, rather than shrinking, public access to these drugs.
WHAT THE BRIDGE PROGRAM ACTUALLY COVERS
Under the Medicare GLP-1 Bridge, eligible Medicare Part D beneficiaries will be able to access Wegovy and Zepbound for a flat $50 monthly copayment. CMS covers the remainder of what officials describe as a roughly $245 monthly program cost. Eligibility requires a body mass index of 35 or above on its own, or 27 or above paired with additional clinical risk factors, and a doctor must submit prior authorization.
CMS Administrator Dr. Mehmet Oz framed the programme in stark terms: ‘These treatments are a major medical advancement, but too many seniors are currently unable to access them due to high cost. The Medicare GLP-1 Bridge changes that by making these medications more affordable and accessible.’ Previously, Medicare Part D plans could only cover GLP-1 drugs when prescribed for a secondary condition such as Type 2 diabetes or cardiovascular risk reduction. The federal law explicitly prohibits Medicare from covering medications prescribed for weight loss alone, a restriction this demonstration programme is specifically designed to work around.
THE CATCH BURIED IN THE STRUCTURE
The Bridge programme’s $50 copayment, crucially, operates entirely outside the standard Part D benefit structure. That means the payment does not count toward a beneficiary’s True Out-of-Pocket costs or their Part D deductible, and beneficiaries who qualify for the Part D Low-Income Subsidy. Typically the patients with the least financial flexibility, cannot apply that subsidy to reduce the $50 further. For lower-income seniors, even a discounted $50 monthly copay can represent a genuine access barrier.
There is also a longer-term transition risk built into the programme’s design. CMS originally planned to follow the Bridge with a permanent, voluntary programme called the BALANCE model beginning January 2027, but announced in May 2026 that BALANCE would be delayed indefinitely while the Bridge itself was extended through December 2027. Beneficiaries using the Bridge now may need to actively switch Part D plans during the 2027 open enrollment period to ensure continued access under whatever structure eventually replaces it. It is a bureaucratic complexity that disproportionately burdens exactly the population, elderly and possibly cognitively vulnerable, least equipped to navigate it smoothly.
WHAT REAL ACCOUNTABILITY LOOKS LIKE HERE
Expanding access to genuinely effective obesity treatment is a defensible, evidence-based public health decision — GLP-1 medications have demonstrated real clinical results, and obesity-linked conditions impose enormous downstream costs on Medicare regardless of how the upfront drug cost is structured. But a programme this consequential should not depend on beneficiaries correctly navigating prior authorization paperwork, plan-switching deadlines, and a Low-Income Subsidy exclusion that specifically disadvantages the poorest enrollees.
CMS must commit, now, to publishing plain-language guidance well before the 2027 open enrollment window, and Congress should treat the Bridge’s eventual success or failure as the evidence base for permanently authorizing Medicare coverage of obesity treatment under ordinary. Deborah Finley got her medication back, eventually, through a sleep apnea diagnosis loophole. Not every patient will be that fortunate, and policy built on loopholes is not policy that deserves to be called durable.
Clear Cut Research Desk
New Delhi, UPDATED: June 26, 2026 01:00 IST
Written By: Tanmay J. Urs
